報價延遲最少15分鐘:2026/01/22 03:55 EST
盤前時段
|
||||
|
-- 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.6238
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.65/--
|
|
企業價值
11.69M
|
| 資產負債 |
|
每股賬面淨值
0.26
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
168.72K
|
|
每股收益
0.03
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 orGen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device. |
